Record:   Prev Next
Title TRAIL, Fas Ligand, TNF and TLR3 in cancer / edited by Olivier Micheau
Imprint Cham : Springer International Publishing : Imprint: Springer, 2017
book jacket
Descript 1 online resource (xiii, 317 pages) : illustrations, digital ; 24 cm
text txt rdacontent
computer c rdamedia
online resource cr rdacarrier
text file PDF rda
Series Resistance to targeted anti-cancer therapeutics, 2196-5501 ; volume 12
Resistance to targeted anti-cancer therapeutics ; volume 12
Note Resistance to TRAIL Pathway-Targeted Therapeutics in Cancer -- TRAIL-R3/R4 and Inhibition of TRAIL Signalling in Cancer -- IAPs and Resistance to Death Receptors in Cancer -- Bcl-2 Proteins and TRAIL Resistance in Melanoma -- Regulation of Caspase-Mediated Apoptosis by the Tumor Suppressor Par-4 -- Stem Cell Regulation by Death Ligands and Their Use in Cell Therapy -- Atypical Immune Functions of CD95/CD95L -- TLR3 is a Death Receptor Target in Cancer Therapy -- Fas/CD95, Lipid Rafts and Cancer -- Role of Sphingolipids in Death Receptor Signalling -- Post-Translational Modifications and Death Receptor Signalling -- System Modeling of Receptor-Induced Apoptosis
This volume provides the current understanding of death receptor's/TLR3 signaling regulation in cancer. Death receptors, including TRAIL-R1, TRAIL-R2, Fas and TNF-RI, owing to their ability to trigger apoptosis and to contribute to the elimination of cancer cells by the immune system have been considered, to variable extent, as important therapeutic targets for cancer therapy. But an increasing body of evidence suggests that some of these receptors may also contribute to tumorigenesis, or that new players such as TLR3 may be targeted for cancer therapy due to their ability to behave like death receptors
Host Item Springer eBooks
Subject Cancer -- Treatment
Cell receptors
Tumor necrosis factor -- Receptors
Cancer Research
Alt Author Micheau, Olivier., editor
SpringerLink (Online service)
Record:   Prev Next